Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT05353543 Not yet recruiting - Clinical trials for Major Depressive Disorder

Acupuncture Therapy Based on Biological Specificity of Acupoints for Major Depressive Disorder

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Acupoints are the stimulus points and reactive points for acupuncture to treat the diseases. Therefore, this study is designed to detect the biological specificity of acupoints in healthy participants and major depressive disorder (MDD) participants by using multiple objective assessment tools. And then acupoints that are statistically different between the two groups will be defined as strong reaction points, and other acupoints without statistically different will be defined as weak response points. In addition, this clinical trial will be conducted to explore whether the efficacy of stimulating strong reaction acupoints is more effective than weak reaction points, thereby confirming the specificity of the acupoint.

NCT ID: NCT05352113 Not yet recruiting - Clinical trials for Major Depressive Disorder

Intradermal Needle Therapy for Major Depressive Disorder

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Major depressive disorder (MDD) is a common mental disorder that affects patients' physical health and quality of life. Although traditional acupuncture therapy has certain advantages in improving MDD, there are still some limitations, such as being time-consuming and some people having a fear of acupuncture. Therefore, intradermal needle therapy will be chosen in the treatment of MDD in this study, which is more convenient, shallow needling, and gentle than traditional acupuncture therapy. The study is designed to investigate the therapeutic effect and safety of intradermal needles for MDD.

NCT ID: NCT05348889 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma (Disorder)

First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies

Start date: August 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).

NCT ID: NCT05348031 Not yet recruiting - Voice Disorders Clinical Trials

Multimodal Analysis of Structural Voice Disorders Based on Speech and Stroboscopic Laryngoscope Video

Start date: May 6, 2022
Phase:
Study type: Observational

This study intends to collect clinical data such as strobary laryngoscope images and vowel audio data of patients with structural voice disorders and healthy individuals, and to establish a multimodal voice disorder diagnosis system model by using deep learning algorithms. Multi-classification of diseases that cause voice disorders can be applied to patients with voice disorders but undiagnosed in clinical practice, thereby assisting clinicians in diagnosing diseases and reducing misdiagnosis and missed diagnosis. In addition, some patients with voice disorders can be managed remotely through the audio diagnosis model, and better follow-up and treatment suggestions can be given to them. Remote voice therapy can alleviate the current situation of the shortage of speech therapists in remote areas of our country, and increase the number of patients who need voice therapy. opportunity. Remote voice therapy is more cost-effective, more flexible in time, and more cost-effective.

NCT ID: NCT05346523 Completed - Emergencies Clinical Trials

Digitalized Differential Diagnosis Broadening in Emergency Rooms

DDX-BRO
Start date: June 9, 2022
Phase: N/A
Study type: Interventional

10 to 35% of patients admitted to an emergency department receive an incorrect diagnosis. Not surprisingly, given the wide variety of health conditions encountered in emergency medicine, physicians often do not consider, remember, or know all possible diagnoses that fit the patient's symptoms. Nowadays, computer software (CDDS) is able to support physicians with a list of possible diagnoses by matching entered patient data to a large database with diagnoses. However, it is still unclear how the use of such a CDDS actually affects the diagnostic quality and workflow in 'real world' ER routine care. Therefore, the aim of this cluster-randomized cross-over trial is to evaluate the consequences of CDDS usage on diagnostic quality, patient outcomes and diagnostic workflow within the ER. Four ER's will provide a CDDS to the diagnosing physicians for specific periods (randomly and alternatingly allocated) in which physicians will be asked to use it for all included study patients. Outcomes between periods with and without the CDDS will be compared. Primary outcome is a diagnostic quality risk score composed of unscheduled ER revisits, unexpected hospitalization (both within 14 days), unexpected intensive medical care unit admission if hospitalized and diagnostic discrepancy between the ER discharge diagnosis and the current diagnosis after 14 days. In total, 1'184 patients will be included.

NCT ID: NCT05341830 Not yet recruiting - Clinical trials for Substance-related Disorders

Housing for Recovery Initiative

Start date: April 18, 2022
Phase: N/A
Study type: Interventional

Recovery housing is a substance-free group home for those exiting drug and alcohol treatment. Individuals live in a recovery-focused environment with others traveling the same journey. Ohio Recovery Housing (ORH) creates and maintains standards of excellence for recovery housing in the state. Each house decides how it operates, with four different "levels" of housing available. These environments have the potential to help build a strong foundation in recovery to improve health, employment, and housing outcomes. ORH and LEO will launch a quasi-experimental study to measure the impact of recovery housing for individuals with substance use disorders. The design relies on variation in the availability of program spots to identify effects. Invitations to join a home will come from a waitlist. As the length of the waitlist is unrelated to applicant characteristics, movement off the waitlist can be considered essentially random. The research team will compare those who receive services to those who do not. The researchers hypothesize that those who participate in recovery housing will have improved health, employment, and housing outcomes compared to individuals who do not receive recovery housing services.

NCT ID: NCT05341219 Recruiting - Opioid Use Disorder Clinical Trials

Light Needle for Opioid Use Disorder

OUD
Start date: March 18, 2022
Phase: N/A
Study type: Interventional

This randomized-controlled study investigates the effect of adjuvant light needle in the treatment of heroin addicts. One hundred heroin addicts older than 20 years old enrolled from the Addiction Treatment Center at Kaohsiung Chang Gung Memorial Hospital and Department of Psychiatry at Kaohsiung Medical University Hospital are randomly allocated to experimental or control group. Subjects in experimental group are treated with light needle on the wrist pulse (Cunkou) 12 times within 4 weeks. Subjects in the control group received a sham light needle treatment, without any laser output. Outcome measurements include check of urine morphine, report of the subjects' times or days of heroin use, self-filling Visual Analogue Scales of heroin craving / refusal of heroin use (0-10 points) during last week, report of the subjects' quality of life using Short Form-12v2, and record of the subject's pulse diagnosis and heart rate variability before and after treatment.

NCT ID: NCT05337969 Completed - Clinical trials for To Determine Bioequivalence Under Fed Conditions

The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Assessed.

Start date: December 2015
Phase: N/A
Study type: Interventional

To evaluate and compare the relative bioavailability and therefore the bioequivalence of fixed dose combination of Metformin and Vildagliptin Tablets 850/50 mg manufactured by Oman Pharmaceuticals Products Co. LLC, Sultanate of Oman, with EUCREAS® 50/850mg tablets manufactured by Novartis Pharma GmbH, Germany, in Normal, Healthy, Adult, Male Human Subjects under Fed Conditions.

NCT ID: NCT05337475 Recruiting - Swallowing Disorder Clinical Trials

Feeding and Swallowing Problems in Infants With Laryngomalacia

Start date: April 1, 2022
Phase:
Study type: Observational

Observational cross-sectional study Infants with laryngomalacia Feeding and swallowing assessment

NCT ID: NCT05333848 Completed - CONTROL Condition Clinical Trials

Effects of Internet-based Storytelling Programs in Reducing Mental Illness Stigma With Mediation by Interactivity and Stigma Content

Start date: December 27, 2020
Phase: N/A
Study type: Interventional

Mental illness stigma has been a concerning issue globally due to its adverse effects on the recovery of people with mental illness and may delay help-seeking for mental health out of the concern of being stigmatized. With technological advancement, Internet-based mental health stigma reduction interventions have been developed to combat mental illness stigma and the effects have been promising. The present study aimed to examine the differential effects of Internet-based storytelling programs varied on level of interactivity and stigma content in reducing mental illness stigma. In the present study, the investigator hypothesized that an Internet-based storytelling program with a combination of interactivity and stigma content would lead to the most significant reduction in public stigma, microaggression, and social distance from people with mental illnesses, followed by Internet-based storytelling program with stigma content-only and interactivity-only, compared with control. Secondly, the investigator hypothesized that the effects observed in stigma reduction would be mediated by perceived autonomy and immersiveness due to the presence of interactivity.